Pfizer acquisition gives Johnson and Johnson increased sales

Johnson & Johnson recorded a sales increase of 16.6 per cent during the fourth quarter of 2007, leading to annual sales growth of 14.6 per cent.

The latest results from the firm show that sales increased around the world, partly due to the acquisition of Pfizer Consumer Healthcare.

Earnings for the year totalled $61.1 billion (31.2 billion pounds) and thanks to the acquisition of Pfizer, the firm saw operational worldwide sales rise by 4.2 per cent over the course of the year.

William C Weldon, chairman and chief executive officer of the firm, said that despite challenges in some markets, the broad business base allowed the firm to return solid results for the year.

“It was a year of significant progress in our pipeline – the successful integration of Pfizer Consumer Healthcare and the creation of new organisational structures focussed on future growth,” he said.

Johnson & Johnson has more than 200 operating companies, making a range of products to treat various different conditions and ailments.